Compare Kinder Morgan Inc (KMI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs ResMed Inc. — how do they compare? Kinder Morgan Inc trades at $31.7 (market cap $70.10B), while ResMed Inc. trades at $223.77 (market cap $32.61B). The key difference: Kinder Morgan Inc is far larger — about 2.1× ResMed Inc.'s market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| KMI | RMD | |
|---|---|---|
Market Cap | $70.10B | $32.61B |
Sector | Energy | Health |
52-Week High | $34.31 | $293.73 |
52-Week Low | $25.84 | $182.82 |
Enterprise Value | $102.15B | $31.97B |
Dividend Yield | 3.75% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.39, up 1.75% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.31% net income margin. Recent news highlights a $5 billion Western Gateway Pipeline joint venture with Phillips 66 and HF Sinclair, signaling growth in energy infrastructure.
The outlook is mixed: robust cash flow and dividend sustainability support income investors, but high debt levels and bearish technical indicators pose risks. Analyst consensus is nearly split between Buy and Hold, reflecting cautious optimism amid valuation concerns.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
